当前位置:首页 - 行情中心 - 诺泰生物(688076) - 财务分析 - 现金流量表

诺泰生物

(688076)

  

流通市值:82.01亿  总市值:119.45亿
流通股本:1.46亿   总股本:2.13亿

现金流量表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金342,632,106.31,041,588,183.29713,280,144.06474,478,534.06
收到的税费返还14,981,186.2329,633,154.5416,627,190.9911,747,999
收到其他与经营活动有关的现金6,318,298.2957,086,554.6516,247,419.738,986,464.8
经营活动现金流入的平衡项目0000
经营活动现金流入小计363,931,590.821,128,307,892.48746,154,754.78495,212,997.86
购买商品、接受劳务支付的现金118,440,850.4348,329,545.56218,696,731.41128,916,479.22
支付给职工以及为职工支付的现金93,743,155.27205,326,441.24147,812,052.9499,617,620.23
支付的各项税费11,684,131.3537,830,870.9229,265,593.8521,346,208.02
支付其他与经营活动有关的现金61,579,191.28186,607,216.81115,214,929.2272,558,216.12
经营活动现金流出的平衡项目0000
经营活动现金流出小计285,447,328.3778,094,074.53510,989,307.42322,438,523.59
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额78,484,262.52350,213,817.95235,165,447.36172,774,474.27
二、投资活动产生的现金流量:
收回投资收到的现金260,000,000550,500,000465,750,000344,750,000
取得投资收益收到的现金242,305.822,903,701.2916,220.94423,319.26
处置固定资产、无形资产和其他长期资产收回的现金净额19,8481,526,616.59168,7361,062,711.99
投资活动现金流入的平衡项目0000
投资活动现金流入小计260,262,153.82554,930,317.79466,834,956.94346,236,031.25
购建固定资产、无形资产和其他长期资产支付的现金167,227,750.52660,639,130.78434,018,903.02247,494,887.63
投资支付的现金500,000,000556,500,000511,500,000315,041,870
投资活动现金流出的平衡项目0000
投资活动现金流出小计667,227,750.521,217,139,130.78945,518,903.02562,536,757.63
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-406,965,596.7-662,208,812.99-478,683,946.08-216,300,726.38
三、筹资活动产生的现金流量:
取得借款收到的现金260,000,000716,682,856.78607,795,759.55470,000,000
发行债券收到的现金-429,094,339.62--
筹资活动现金流入平衡项目0000
筹资活动现金流入小计260,000,0001,145,777,196.4607,795,759.55470,000,000
偿还债务支付的现金104,254,586449,486,062.44438,457,129.55363,100,000
分配股利、利润或偿付利息支付的现金5,454,501.2257,614,716.5352,849,075.2349,488,892.07
支付其他与筹资活动有关的现金1,809,761.36,780,435.53,509,154.462,972,002.25
筹资活动现金流出平衡项目0000
筹资活动现金流出小计111,518,848.52513,881,214.47494,815,359.24415,560,894.32
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额148,481,151.48631,895,981.93112,980,400.3154,439,105.68
四、汇率变动对现金及现金等价物的影响986,035.2-3,213,148.59-1,543,074.98-689,556.16
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-179,014,147.5316,687,838.3-132,081,173.3910,223,297.41
加:期初现金及现金等价物余额677,532,732.81360,844,894.51360,844,894.51360,844,894.51
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额498,518,585.31677,532,732.81228,763,721.12371,068,191.92
补充资料:
净利润-165,452,661.96-39,851,244.79
资产减值准备-5,240,686.62-12,621,093.23
固定资产和投资性房地产折旧-122,159,797.56-59,563,131.69
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-122,159,797.56-59,563,131.69
无形资产摊销-9,613,020.3-4,465,910.42
长期待摊费用摊销-4,606,685.27-2,704,265.05
处置固定资产、无形资产和其他长期资产的损失--176,417.14--95,202.3
固定资产报废损失-15,299,301.21-5,696,502.6
公允价值变动损失--257,516.79-2,773,494.43
财务费用-17,457,703.51-7,454,786.54
投资损失--2,903,701.2--931,449.26
递延所得税--13,564,408.2-7,740,174.24
其中:递延所得税资产减少--12,956,181.15-8,382,376.25
递延所得税负债增加--608,227.05--642,202.01
存货的减少--82,583,118.21--24,003,711.42
经营性应收项目的减少--126,486,832.98-38,960,857.69
经营性应付项目的增加-180,380,119.28-13,546,934.03
其他-23,304,970.5-342,699.32
现金的期末余额-677,532,732.81-371,068,191.92
减:现金的期初余额-360,844,894.51-360,844,894.51
公告日期2024-04-232024-03-292023-10-212023-08-29
审计意见(境内)标准无保留意见
TOP↑